Replies to post #218634 on Biotech Values

[jbog]

Mufaso,

In 2017 Botox Worldwide Sales were approximately $3.16 Billion which breaks down as follows:

U.S. Total Botox Revenue $2.254 Billion:
U.S. Cosmetic $812 Million (36% of U.S. Sales)
U.S. Hyperhidrosis $67.2 Million (3% of U.S. Sales)
U.S. Therapeutic $1.375 Billion (61% of U.S. Sales)

International Total Revenue $914.5 Million:
International Cosmetics $557 Million
International Therapeutics 357.5 Million

While I agree that Botox has exhibited tremendous growth, I certainly can't see where Revance will garner anywhere near the dollar amount in 10 years.

The U.S. portion is driven by Therapeutics and Revance will need to run many trials and show a benefit to gain traction. I'm not sold on them capturing a big portion of the Cosmetic area because it'll prove to be detrimental to the plastic surgeon.

Once Revance hits the market it'll be critical of how the market it to the public.

Time will tell.